Lapatinib;231277-92-2
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: L079000
English Name: Lapatinib
English Alias: N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine
CAS Number: 231277-92-2
Molecular Formula: C₂₉H₂₆ClFN₄O₄S
Molecular Weight: 581.06
Product Advantages: As a dual-target tyrosine kinase inhibitor, Lapatinib has highly selective targeting inhibition, effectively suppressing the signaling of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). With a stable chemical structure and excellent pharmacokinetic properties, it shows high oral bioavailability, over 99% plasma protein binding rate, and a clear metabolic pathway (mainly via CYP3A4 enzyme). It demonstrates good safety and efficacy in clinical applications, particularly suitable for combination therapy of HER2-positive breast cancer.
Application Fields:
Clinical Treatment: Mainly used for treating advanced or metastatic HER2-positive breast cancer patients who have received prior therapy including anthracyclines, taxanes, and trastuzumab. It can be used in combination with capecitabine, and also for treating hormone receptor-positive HER2-positive breast cancer.
Drug Research and Development: Used as a reference standard for quality control, impurity analysis, and biological sample detection of Lapatinib-related formulations; applied in preclinical studies to evaluate the drug's efficacy, toxicity, and mechanism of action.
Basic Research: Serves as a tool compound for basic medical research related to EGFR/HER2 signaling pathways, exploring the mechanisms of tumor occurrence and development.
Background Description: Breast cancer is one of the most common malignant tumors in women worldwide, among which HER2-positive breast cancer accounts for about 20%-30%, featuring strong invasiveness and poor prognosis. Traditional chemotherapy drugs have limited efficacy for HER2-positive breast cancer, while Lapatinib, by dual inhibition of EGFR and HER2, blocks the signaling of tumor cells and inhibits tumor growth, providing new treatment options for HER2-positive breast cancer patients. Its research and development are based on in-depth studies of the tyrosine kinase receptor signaling pathway, representing an important breakthrough in the field of targeted therapy.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
